ClinicalTrials.gg
RecruitingNCT00026884Updated Nov 9, 2026

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

An observational study in Malignant Neoplasms, Hereditary Neoplastic Syndromes and Kidney Cancer, sponsored by National Cancer Institute (NCI). Recruiting at 1 site in United States. Open to participants aged 2 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by National Cancer Institute (NCI) · Observational

From the registry’s dates

  • Started Mar 1998; still recruiting 28 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,950
Ages
2 Years and older
Sex
All
01

Study summary

Selected individuals suspected of having or with prior biopsy proof of malignant disease will be seen in the Urologic Oncology Branch, NCI. Blood samples may be collected at the time of the initial visit and at periodic intervals during the course of the disease. These samples will be stored in the tissue bank of the Urologic Oncology Branch. Aliquots of malignant and normal tissue will be collected at the time of surgery and stored in the tissue bank, Urologic Oncology Branch, NCI. These materials will be used in the research efforts of the Urologic Oncology Branch, NCI.

Read the detailed description

Background

Kidney, prostate, bladder, testis and penile cancer account for 22% of cancers diagnosed in the United States and are responsible for 10% of cancer deaths each year in the U.S. Understanding the genes and gene pathways that cause genitourinary malignancies will provide the foundation for the development of targeted therapeutic agents for patients affected with these cancers. Since 1982 investigators in the Urologic Oncology Branch have been studying the genetic basis of urologic cancers. The identification of the genes for cancer of the kidney has led to the approval by the FDA of a number of new agents for patients with advanced disease. It is our goal to study the cancer gene pathways of genitourinary malignancies in order to further understand the cancer gene pathways that cause these diseases.

Objectives

  • Collection of benign and malignant tissue from patients with known or suspected cancer
  • Collection of benign and malignant tissue from patients with rare inherited conditions associated with an increased risk for kidney cancer
  • Determine the molecular genetic differences between normal and tumorigenic tissues
  • Investigate the categories of genes/ biochemical pathways such as those that influence the cell cycle, angiogenesis, metabolic changes, and metastatic potential
  • Examine protein expression and bioimmunoassays investigating potential genetic markers
  • Investigate cellular/biochemical response to existing and novel therapeutic agents.
  • Investigate quality of life in men who have prostate cancer
  • Investigate molecular genetic basis of urologic malignancies
  • Examine cell free DNA and circulating tumor DNA for cancer gene mutations

Eligibility

  • Individuals with biopsy-proven malignant disease
  • Individuals suspected of having malignant disease
  • Individuals with known or suspected inherited urologic malignant disorder
  • A relative (related by blood) of an individual with a confirmed or suspected diagnosis of an inherited genitourinary disorder or malignancy
  • Family members of patients with a DNA variant

Design

  • Participants will be screened for eligibility in the Urologic Oncology Branch Clinic
  • Blood and urine samples may be obtained
  • Normal and malignant tissue may be collected from participants undergoing clinically indicated surgical procedures
  • Basic scientific research will be performed on collected specimens
  • Participants will have the option to be contacted if a result is detected that would affect their health and they will be given the opportunity to be evaluated and re-tested on an IRB approved protocol if available
  • Germline and somatic whole genome exome sequencing may be performed
02

Conditions studied

  • Malignant Neoplasms
  • Hereditary Neoplastic Syndromes
  • Kidney Cancer
  • Renal Cancer
  • Bladder Cancer

Keywords

  • Serum
  • Collection of Tissue
  • Malignant Disease
  • Molecular Basis
  • Genome Sequencing
  • Natural History
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 5,950 is above the median of 200 across 2,641 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 336 are open to participants now.

Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

1. Individuals with biopsy-proven malignant disease 2. Individuals suspected of having malignant disease 3. Individuals with known or suspected urologic malignant disorders who have clinically indicated urologic or non-urologic surgical lesion 4. Family members of individuals suspected of having an inherited genitourinary malignancy 5. Family members of individuals with a DNA variant

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals with -proven malignant disease
  • Individuals suspected of having a malignant disease
  • Individuals who have or are suspected of having an inherited genitourinary malignant disorder
  • Participants must be >= 2 years of age
  • A relative (related by blood) of an individual with a confirmed or suspected diagnosis of a malignant disease or an inherited genitourinary malignant disorder.
  • All participants and parents/guardians, for children younger than 18 years of age, must sign an document indicating their understanding of the nature and the risks of this study before any protocol related studies are performed.

Exclusion criteria

EXCLUSION CRITERIA:

-Individuals whose co-morbidities preclude surgical intervention.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,950 participants (estimated)

Groups and cohorts

  • Family Members

    Family members (related by blood) of participants who have or are suspected of having a malignant disease or an inherited genitourinary malignant disorder

  • Participants

    Participants with biopsy-proven malignant diseases; or participants suspected of having a malignant disease; or participants who have or who are suspected of having an inherited genitourinary malignant disorder

06

What researchers measure

Primary outcomes

  1. Investigate quality of life in men who have prostate cancer.

    Prostate cancer participants that have improvement in quality of life

    Time frame: on-going

  2. Investigate molecular genetic basis of urologic malignancies

    Investigate molecular genetic basis of urologic malignancies

    Time frame: on-going

  3. Investigate cellular/biochemical response to existing and novel therapeutic agents.

    Collection of blood, urine, saliva, and/or benign and malignant tissue

    Time frame: on-going

  4. Examine protein expression and bioimmunoassays investigating potential genetic markers.

    Detection and expression analysis of gene(s)

    Time frame: on-going

  5. Determine the molecular genetic differences between normal and tumorigenic tissues.

    Molecular genetic differences between normal and tumorigenic tissues

    Time frame: on-going

  6. Collection of benign and malignant tissue from individuals with rare inherited conditions associated with an increased risk for kidney cancer.

    Collection of blood, urine, saliva, and/or benign and malignant tissue

    Time frame: on-going

  7. Collection of benign and malignant tissue from individuals with known or suspected cancer.

    Collection of blood, urine, saliva, and/or benign and malignant tissue

    Time frame: on-going

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • For more information at the NIH Clinical Center contact National Cancer Institute Referral Office · Contact888-624-1937
08

References and documents

Publications

  • Merriman KM, Harmon SA, Belue MJ, Yilmaz EC, Blake Z, Lay NS, Phelps TE, Merino MJ, Parnes HL, Law YM, Gurram S, Wood BJ, Choyke PL, Pinto PA, Turkbey B. Comparison of MRI-Based Staging and Pathologic Staging for Predicting Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. AJR Am J Roentgenol. 2023 Dec;221(6):773-787. doi: 10.2214/AJR.23.29609. Epub 2023 Jul 5. PubMed 37404084 ↗

Individual participant data

Plan to share: Yes — All IPD recorded in the medical record will be shared with intramural investigators upon request. @@@@@@In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Clinical data available during the study and indefinitely.@@@@@@Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.

Access criteria: Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.@@@@@@Genomic data are made available via dbGaP through requests to the data custodians.

09

Timeline

6 registry updates since Sep 25, 2026

Started Mar 1998 (actual).

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2001
First posted
Nov 15, 2001
StartActual
Mar 12, 1998
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and description
6 updates, last Nov 9, 2026
Show all 6 updates
  1. Nov 9, 2026
    Minor edits only
    + 1 other change: description
  2. Nov 5, 2026
    Minor edits only
    + 1 other change: description
  3. Nov 4, 2026
    Minor edits only
    + 1 other change: verification date
  4. Oct 26, 2026
    Minor edits only
    + 1 other change: description
  5. Oct 16, 2026
    Minor edits only
    + 2 other changes: verification date and description
  6. Sep 30, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT00026884
Responsible party
Sponsor
First posted
Nov 15, 2001
Start date
Mar 12, 1998
Last update
Nov 9, 2026

Study contacts

Deborah A Nielsen, R.N.
Contact
deborah.nielsen@nih.gov
(240) 760-6247
W. Marston Linehan, M.D.
Contact
linehanm@mail.nih.gov
(240) 858-3700
W. Marston Linehan, M.D.
principal investigator · National Cancer Institute (NCI)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion